Artelo Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Cash and Investments Balance Quarterly10.3MTarget: Sufficient to fund operations into late 2026
ART26.12 Multiple Ascending Dose (MAD) Study Enrollment QuarterlyTarget: Initiation of enrollment in Q4 2026
ART27.13 Glaucoma Pilot Study Enrollment QuarterlyTarget: First patient enrollment in Q2 2026
Watch Items
- ART26.12 Multiple Ascending Dose (MAD) Study ProgressTrigger: Delay in initiating enrollment beyond Q4 2026Action: Re-evaluate clinical timeline and cash runway projections
- ART27.13 Phase 2 CAReS Trial Strategic PartnershipsTrigger: Execution of a co-development or licensing agreementAction: Assess impact on capital allocation and long-term R&D expenses
- Cash Runway and Capital RaisesTrigger: Cash balance falling below $3.0 million without non-dilutive fundingAction: Evaluate dilutive equity offerings or alternative financing structures
Research as of 20 Jun 2026